A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronarya artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the Veln-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial

Canadian Journal of Cardiology

Volumn 25, Issue 9, 2009, Pages 509-515

  Bertrand, Oliver F ^a   Poirier, Paul ^a   Rodés Cabau, Josep ^a   Rinfret, Stéphane ^b   Title, Lawrence ^c   Dzavik, Vladimir ^d   Natarajan, Madhu ^e   Angel, Juan ^f   Batalla, Nuria ^f   Alméras, Natalie ^a   Costerousse, Olivier ^a   De Larochellière, Robert ^a   Roy, Louis ^a   Després, Jean Pierre ^a  

^a LAVAL UNIVERSITY   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Atherosclerosis; Cardiovascular risk factors; Catheterization; Coronary artery disease; Diabetes mellitus; Graft patency; Intravascular ultrasound; Metabolic syndrome

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; VASODILATOR AGENT;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY COMPOSITION; BODY FAT DISTRIBUTION; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; AGED; ANGINA PECTORIS; BLOOD; CANADA; COMPARATIVE STUDY; FOLLOW UP; GLUCOSE BLOOD LEVEL; METABOLISM; METHODOLOGY; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; SPAIN; TREATMENT OUTCOME;

ADULT; AGED; ANGINA PECTORIS; ATHEROSCLEROSIS; BLOOD GLUCOSE; CORONARY ARTERY BYPASS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; QUEBEC; SPAIN; THIAZOLIDINEDIONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 70349572343     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70136-9     Document Type: Article

References (42)

1. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Ann Rev Med 2001;52:239-57.
2. Nesto RW, Libby P. Diabetes mellitus and the cardiovascular system. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease. A Textbook of Cardiovascular Medicine, 6th edn. Philadelphia: WB Saunders, 2001:2133-50.
3. Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV. A randomized controlled trial. JAMA 2005;294:2446-54.
4. Domanski M, Borkowf C, Campeau L, et al. Prognostic factors for atherosclerosis progression in saphenous vein grafts. The Postcoronary Artery Bypass Graft (Post-CABG) trial. J Am Coll Cardiol 2000;36:1877-83.
5. Bulkley BH, Hutchins GM. Accelerated "atherosclerosis". A morphologic study of 97 saphenous vein coronary artery bypass grafts. Circulation 1977;55:163-9.
6. Bourassa MG, Enjalbert M, Campeau L, Lesperance J. Progression of atherosclerosis in coronary arteries and bypass grafts: Ten years later. Am J Cardiol 1984;53:102C-7C.
7. Campeau L, Enjalbert M, Lesperance J, Vaislic C, Grondin CM, Bourassa MG. Atherosclerosis and late closure of aortocoronary saphenous vein grafts: Sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery. Circulation 1983;68:II1-7.
8. Widimsky P, Straka Z, Stros P, et al. One-year coronary bypass graft patency: A randomized comparison between off-pump and on-pump surgery angiographic results of the PRAGUE-4 trial. Circulation 2004;110:3418-23.
9. Bose D, von Birgelen C, Erbel R. Intravascular ultrasound for the evaluation of therapies targeting coronary atherosclerosis. J Am Coll Cardiol 2007;49:925-32.
10. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16.
11. Nissen SE, Tuzcu EM, Brewer HB, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006;354:1253-63.
12. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004;291:1071-80.
13. Rodes-Cabau J, Facta A, Larose E, et al. Predictors of aortosaphenous vein bypass narrowing late after coronary artery bypass grafting. Am J Cardiol 2007;100:640-5.
14. Hausmann D, Erbel R, Alibelli-Chemarin MJ, et al. The safety of intracoronary ultrasound. A multicenter survey of 2207 examinations. Circulation 1995;91:623-30.
15. Mintz GS, Nissen SE, Anderson WD, et al. J Am Coll Cardiol Clinical Expert Consensus Document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001;37:1478-92.
16. Hozumi T, Yoshikawa J, Yoshida K, et al. Use of intravascular ultrasound for in vivo assessment of changes in intimal thickness of angiographically normal saphenous vein grafts one year after aortocoronary bypass surgery. Heart 1996;76:317-20.
17. Kaneda H, Terashima M, Takahashi T, et al. Mechanisms of lumen narrowing of saphenous vein bypass grafts 12 months after implantation: An intravascular ultrasound study. Am Heart J 2006;151:726-9.
18. Keren G, Douek P, Oblon C, Bonner RF, Pichard AD, Leon MB. Atherosclerotic saphenous vein grafts treated with different interventional procedures assessed by intravascular ultrasound. Am Heart J 1992;124:198-206.
19. Komiyama N, Nakanishi S, Nishiyama S, Seki A. Intravascular imaging of serial changes of disease in saphenous vein grafts after coronary artery bypass grafting. Am Heart J 1996;132:30-40.
20. Poirier P. Adiposity and cardiovascular disease: Are we using the right definition of obesity? Eur Heart J 2007;28:2047-8.
21. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006;26:968-76.
22. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918.
23. Pascot A, Despres JP, Lemieux I, et al. Contribution of visceral obesity to the deterioration of the metabolic risk profile in men with impaired glucose tolerance. Diabetologia 2000;43:1126-35.
24. Peiris AN, Sothmann MS, Hoffmann RG, et al. Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med 1989;110:867-72.
25. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. Evaluation and management of atherogenic dyslipidemia: Beyond low-density lipoprotein cholesterol. CMAJ 2001;165:1331-3.
26. Peiris AN, Struve MF, Mueller RA, Lee MB, Kissebah AH. Glucose metabolism in obesity: Influence of body fat distribution. J Clin Endocrinol Metab 1988;67:760-7.
27. Poirier P, Lemieux J, Mauriege P, et al. Impact of waist circumference on the relationship between blood pressure and insulin: The Quebec Health Survey. Hypertension 2005;45:363-7.
28. Pouliot MC, Despres JP, Nadeau A, et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992;41:826-34.
29. Marx N, Libby P, Plutzky J. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: Possible mediators of cardiovascular risk? J Cardiovasc Risk 2001;8:203-10.
30. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998;83:1097-103.
31. Borchert M, Schondorf T, Lubben G, Forst T, Pfutzner A. Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function. Diabetes Technol Ther 2007;9:410-20.
32. Duez H, Fruchart JC, Staels B. PPARS in inflammation, atherosclerosis and thrombosis. J Cardiovasc Risk 2001;8:187-94.
33. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007;153:445.e1-6.
34. de Souza CJ, Eckhardt M, Gagen K, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001;50:1863-71.
35. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-91.
36. Virtanen KA, Hallsten K, Parkkola R, et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 2003;52:283-90.
37. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
38. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-51.
39. Takeda Pharmaceutical Company. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCI) tablets for type 2 diabetes mellitus (Letter to health care providers). Osaka: Takeda Pharmaceutical Company, 2007.
40. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-80.
41. Meltzer S, Leiter L, Daneman D, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ 1998;159(Suppi 8):S1-29.
42. Yale J, Beggs I, Gerstein HC, et al. Canadian Diabetes Association Clinical Practice Guidelines for the prevention and management of hypoglycemia in diabetes. Can J Diab 2001;26:22-35.